FABP

FABP製品

  • All (4)
  • FABP阻害剤 (3)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S6622 BMS309403 BMS309403 is a small-molecule FABP4 inhibitor with nM affinity (Kd=4 nM for FABP4) and >100-fold selectivity against FABP5 as well as the heart isoform FABP3.
mBio, 2025, e0218025.
Sci Rep, 2025, 15(1):30552
Kidney Dis (Basel), 2025, 11(1):75-89
F1600 FABP4 Antibody [M24L23]
S9957 SBFI-26 SBFI-26 competitively inhibits the activities of FABP5 and FABP7.
World J Clin Oncol, 2024, 15(1):130-144
E4780New ART26.12 ART26.12 is an inhibitor of fatty acid-binding protein 5 (FABP5) that selectively binds to FABP5 over FABP3, FABP4, and FABP7, exhibiting antinociceptive properties. It alleviates oxaliplatin-induced pain through lipid modulation and cannabinoid receptor activation, with potential for preventing and treating oxaliplatin-induced peripheral neuropathy (OIPN).
S6622 BMS309403 BMS309403 is a small-molecule FABP4 inhibitor with nM affinity (Kd=4 nM for FABP4) and >100-fold selectivity against FABP5 as well as the heart isoform FABP3.
mBio, 2025, e0218025.
Sci Rep, 2025, 15(1):30552
Kidney Dis (Basel), 2025, 11(1):75-89
S9957 SBFI-26 SBFI-26 competitively inhibits the activities of FABP5 and FABP7.
World J Clin Oncol, 2024, 15(1):130-144
E4780New ART26.12 ART26.12 is an inhibitor of fatty acid-binding protein 5 (FABP5) that selectively binds to FABP5 over FABP3, FABP4, and FABP7, exhibiting antinociceptive properties. It alleviates oxaliplatin-induced pain through lipid modulation and cannabinoid receptor activation, with potential for preventing and treating oxaliplatin-induced peripheral neuropathy (OIPN).
E4780New ART26.12 ART26.12 is an inhibitor of fatty acid-binding protein 5 (FABP5) that selectively binds to FABP5 over FABP3, FABP4, and FABP7, exhibiting antinociceptive properties. It alleviates oxaliplatin-induced pain through lipid modulation and cannabinoid receptor activation, with potential for preventing and treating oxaliplatin-induced peripheral neuropathy (OIPN).